Literature DB >> 28529115

Pneumococcal infection in patients with systemic lupus erythematosus.

Juliet Schurder1, Tiphaine Goulenok1, Romain Jouenne1, Antoine Dossier1, Damien Van Gysel2, Thomas Papo3, Karim Sacre4.   

Abstract

OBJECTIVE: Our study aimed to analyze the risk factors associated with the occurrence and severity of pneumococcal infection (PI) in systemic lupus erythematosus (SLE) patients.
METHODS: Medical records of all SLE patients admitted in our department from January 2005 to December 2014 were retrospectively reviewed. SLE patients were separated in 2 groups according to whether they had PI or not. Medical records of all consecutive patients (with and without SLE) admitted in our department for PI over the same period of time were also reviewed. Clinical characteristics associated with PI occurrence and severity were analyzed in SLE patients.
RESULTS: One hundred and ninety SLE patients (42.2+14.9 years; 87.4% females) were hospitalized over a 10-year period. PI was the reason for admission in 6 (3.2%) patients, including 5 cases of invasive infection. With a follow-up of 2112.8 patient-years for the total cohort, incidence of invasive PI in SLE was of 236/100,000 patient-years. PI occurred at a younger age (43.5+14.9 versus 65.3+18.7 years, P<0.01) and were more severe, with a higher frequency of invasive infection (P<0.001) and higher need for ICU admission (P<0.05) in SLE as compared to non SLE patients. Risk factors associated with PI in SLE patients were a serum gammaglobulin level<5g/L (P<0.01) and a past history of lupus nephritis (P<0.05), only. Steroids (P<0.001) and immunosuppressive drugs (P<0.05) were associated with infection severity.
CONCLUSION: SLE is a disease of high susceptibility for invasive pneumococcal infections. Our study points to the need for vaccination against Streptococcus pneumoniae in SLE.
Copyright © 2017 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Pneumococcal infection; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 28529115     DOI: 10.1016/j.jbspin.2017.05.012

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  5 in total

1.  Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic.

Authors:  M Krasselt; C Baerwald; O Seifert
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

2.  Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy.

Authors:  Hannah M Garcia Garrido; Albert Vollaard; Geert R D'Haens; Phyllis I Spuls; Frederike J Bemelman; Michael W Tanck; Godelieve J de Bree; Bob Meek; Martin P Grobusch; Abraham Goorhuis
Journal:  Vaccines (Basel)       Date:  2022-05-17

Review 3.  Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease.

Authors:  Michael Battaglia; Lee Ann Garrett-Sinha
Journal:  J Transl Autoimmun       Date:  2020-12-23

4.  Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus.

Authors:  Chiara Cantarelli; Chiara Guglielmo; Susan Hartzell; Fadi El Salem; Sofia Andrighetto; Victor P Gazivoda; Enrico Fiaccadori; Gaetano La Manna; Gianluigi Zaza; Jeremy Leventhal; Ioannis Tassiulas; Paolo Cravedi
Journal:  Front Immunol       Date:  2019-11-20       Impact factor: 7.561

5.  Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Authors:  Victoria Furer; Christien Rondaan; Marloes Heijstek; Sander van Assen; Marc Bijl; Nancy Agmon-Levin; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha Crnkic Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.